Angiodynamics Stock Earnings Reports

AngioDynamics reported a strong start to fiscal 2026 with pro forma revenue of $75.7M, up 12.2% year-over-year. Growth was led by the Med Tech segment (+26.1%), which now represents 47% of revenue, driven by continued adoption of Auryon (17 consecutive quarters of double-digit growth), Mechanical Thrombectomy (AngioVac & AlphaVac +41.2%), and NanoKnife (+26.7%). Gross margin improved to 55.3% (up ~90 bps) driven by pricing, favorable mix toward higher-margin Med Tech products, and operational efficiencies, although tariffs (~$1.7M in Q1; $4M–$6M expected for FY26) remain a headwind. Operating expense discipline produced an adjusted net loss of $4.2M (loss per share $0.10) and adjusted EBITDA of $2.2M (vs. a loss in prior year). Cash was $38.8M at quarter end with zero debt; management expects to be cash-flow positive for FY26 with seasonal cash use in Q2 and Q3 and strong generation in Q4. Management raised full-year guidance: net sales now expected $308M–$313M (up from $305M–$310M), Med Tech growth now guided to +14%–16%, gross margin 53.5%–55.5%, adjusted EBITDA $6M–$10M, and adjusted loss per share $0.33–$0.23. Company is investing in commercial expansion (added Mechanical Thrombectomy sales reps to ~50 territories and plans further NanoKnife urology selling capacity), continued R&D (~target ~10% of sales), and clinical programs (AMBITION BTK for Auryon and NanoKnife reimbursement code implementation Jan 1). Overall message: accelerating med-tech-led growth, improving profitability, targeted investments to scale new high-growth franchises.